Advances in Cancer Immunotherapy 2024: Annual Update

Please Note:
This course has two components you can register for. You can either register for the symposium only, Immunotherapy Toxicities session only, or both 

Cancer treatment has evolved significantly over the past decade from a treatment paradigm anchored on surgery, chemotherapy, and radiotherapy, to one embracing molecularly-targeted therapies disrupting tumor-specific signaling pathways, as well as new approaches to mobilize the immune system. For clinicians trying to keep current with advancing immuno-oncology principles and research, the pace of these developments has brought new challenges. Recognizing these challenges, this course will provide a comprehensive clinical review of the advances taking place in the immuno-oncology field.

This year we have added an optional session on Immunotherapy Toxicities, focusing on the identification and management of common and uncommon toxicities from immune-checkpoint inhibitors. Attendance at this session, entitled “Sink or Swim: Navigating the Murkey Waters of Immunotherapy Toxicities” is optional and available for an additional fee. It will take place after the close of the general session on the second day. Attendance at the Advances in Cancer Immunotherapy symposium is NOT required to attend this toxicities session, you may register to ONLY attend this part of the program.

Target audience

This activity is intended for physicians, nurses, physician assistants, and other members of the healthcare team.

Learning objectives

Upon completion of this activity, participants will be able to:

1. Evaluate cancer immunotherapy principles and strategies and how they influence current treatment approaches.
2. Identify the emerging role of personalized cancer vaccination and other immunotherapy combinations in patients with solid tumor and hematologic malignancies.
3. Define currently approved and emerging predictive biomarkers for cancer immunotherapy.
4. Recognize and implement management strategies for immune-mediated side effects in patients treated with immunotherapy agents.
5. Recognize the importance of establishing a multidisciplinary approach in the immunotherapy era.

For exhibit space, please contact ebrooks3@mgb.org

Registration instructions

Cancellation Policy:
Registrations cancelled on or before October 31, 2024 will be refunded, less a $35 administrative fee. Registrations cancelled after October 31, 2024 will not be refunded.

Contact partnerscpd@partners.org if you require assistance in cancelling your online registration.

Additional information

Massachusetts General Hospital Cancer Center & Mass General Brigham 

Faculty credentials

Course Directors

Justin Gainor, MD
Director, Center for Thoracic Cancers,
Director of Targeted Immunotherapy,
Massachusetts General Hospital Cancer Center;
Associate Professor of Medicine, Harvard Medical School

Krista Rubin, MS, FNP-BC
Nurse Practitioner, Center for Melanoma,
Massachusetts General Hospital Cancer Center

Ryan Sullivan, MD
Physician Investigator, Cancer Center, Mass General Research Institute;
Assistant In Medicine, Hematology-Oncology, Massachusetts General Hospital;
Associate Professor of Medicine, Harvard Medical School

Faculty

Steven Blum, MD
Instructor in Medicine,
Massachusetts General Hospital

Priscilla Brastianos, MD
Associate Professor of Medicine, Harvard Medical School;
Physician Investigator, Mass General Research Institute;
Assistant Physician, Massachusetts General Hospital Cancer Center

Daniel P. Cahill, MD, PhD
Professor of Neurosurgery, Harvard Medical School;
Neurosurgical Oncologist, Department of Neurosurgery,
Massachusetts General Hospital

Michael Dougan, MD, PhD
Massachusetts General Hospital

Riley Fadden, MSN, RN, FNP-C
Nurse Practitioner, Center for Melanoma,
Massachusetts General Hospital Cancer Center

Alexander Faje, MD
Massachusetts General Hospital

Christine Freedman, RN
Massachusetts General Hospital Cancer Center

Xin Gao, MD
Assistant in Medicine, Massachusetts General Hospital Cancer Center;
Assistant Professor, Harvard Medical School

Elizabeth Gerstner, MD
Associate Professor of Neurology, Harvard Medical School;
Department of Neurology, Massachusetts General Hospital

Amanda Guidon, MD, MPH
Massachusetts General Hospital

Rakesh Jain, PhD
Director, Steele Laboratory, Massachusetts General Hospital;
A. Werk Cook Professor of Radiation Oncology, Harvard Medical School

Howard Kaufman, MD
Assistant in Surgery, Surgery, Massachusetts General Hospital;
Lecturer in Surgery, Harvard Medical School

Florence (Katie) Keane, MD
Assistant Professor in Radiation Oncology,
Massachusetts General Hospital

Meghan Mooradian, MD
Instructor, Medicine, Harvard Medical School;
Clinical Oncologist, Medial Oncology,
Massachusetts General Hospital Cancer Center

Iman Osman, MD
Rudolf L. Baer Professor of Dermatology,
Ronald O. Perelman Department of Dermatology,
Professor, Department of Medicine,
Professor, Department of Urology,
NYU Langone Health

Patrick Ott, MD, PhD
Clinical Director, Melanoma Disease Center,
Director, Clinical Sciences, Center for Immuno-Oncology,
Dana-Farber Cancer Institute;
Associate Professor of Medicine, Harvard Medical School

Jong Chul Park, MD
Assistant Professor of Medicine,
Massachusetts General Hospital Cancer Center

Michael Parsons, PhD
Associate Professor of Psychology, Harvard Medical School;
Neuropsychologist, Pappas Neuro-Oncology Center, Department of Psychiatry,
Massachusetts General Hospital

Laura Petrillo, MD
Palliative Care Physician, Massachusetts General Hospital;
Assistant Professor of Medicine, Harvard Medical School

Kerry Reynolds, MD
Clinical Director, Inpatient Oncology Units,
Director, Severe Immunotherapy Complications Program,
Massachusetts General Hospital Cancer Center

Sherin J. Rouhani, MD, PhD
Inpatient Oncologist,
Massachusetts General Hospital Cancer Center

Kurt Schalper, MD, PhD
Associate Professor of Pathology,
Director, Translational Immuno-oncology Laboratory,
Yale School of Medicine

Arlene Sharpe, MD, PhD
Kolokotrones University Professor,
Chair, Department of Immunology,
Harvard Medical School

Nathaniel Treister, DMD, DMSc
Brigham & Women’s Hospital

Alexandra-Chloe Villani, PhD
Director, Single-Cell Genomics Program,
Center for Immunology and Inflammatory Diseases,
Massachusetts General Hospital;
Assistant Professor of Medicine, Harvard Medical School;
Associate Scientist, Broad Institute of MIT and Harvard

Oladapo Yeku, MD, PhD, FACP
Physician Investigator, Mass General Research Institute;
Assistant Professor of Medicine, Harvard Medical School;
Assistant in Medicine, Massachusetts General Hospital Cancer Center

Accreditation

In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AMA PRA Category 1 Credits^TM
Mass General Brigham designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing
Mass General Brigham designates this activity for 13.5 ANCC contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

Please note: up to 13.5 credits will be awarded if you attend both the symposium AND Immunotherapy Toxicities optional session.

If you attend the symposium only, you will be awarded up to 11.5 credits.
If you attend the Immunotherapy Toxicities optional session only, you will be awarded up to 2 credits.

MOC Recognition Statement 
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 13.5 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note: up to 13.5 MOC points will be awarded if you attend both the symposium AND Immunotherapy Toxicities optional session.

If you attend the symposium only, you will be awarded up to 11.5 MOC points.
If you attend the Immunotherapy Toxicities optional session only, you will be awarded up to 2 MOC points.
 

Program

Thursday, November 14, 2024 | 7:30am – 4:00pm

*The exhibit hall will be open during breakfast, breaks, and lunch
 

Friday, November 15, 2024 | 7:30am – 1:00pm
Optional Toxicities Session: 1:30pm – 3:50pm

*The exhibit hall will be open during breakfast, breaks, and lunch

Sink or Swim: Navigating the Murky Waters of Immunotherapy Toxicities
Identification and management of common and uncommon toxicities from immune-checkpoint inhibitors